Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 35, Issue 6, 2002, Pages 629-633

  Santos, Mácia A ^a   Marques, Raynério C ^a   Farias, Carolinne A ^a   Vasconcelos, Danielle M ^a   Stewart, Jay M ^b   Costa, Dorcas L ^a   Costa, Carlos H N ^a,c  

^a FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Hosp de Doencas Infecto Contagiosas   (Brazil)

Author keywords

Amphotericin B; Antimony; Therapy; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIMONY DERIVATIVE;

ARTICLE; BRAZIL; CHEMOPROPHYLAXIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; INFANT; MULTIVARIATE ANALYSIS; VISCERAL LEISHMANIASIS;

BACTERIA (MICROORGANISMS);

EID: 0036869986     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0037-86822002000600014     Document Type: Article

References (27)

1. Badaro R, Jones T, Lorenço R, Cerf BJ, Sampaio D, Carvalho EM, Rocha H, Teixeira R, Johnson Jr WD. A prospective study of visceral leishmaniasis in an endemic area of Brazil. Journal Infection Disease 154: 639-649, 1986.
2. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clinical Infection Disease 24: 684-703, 1997.
3. Bryceson A. Therapy in man. In: Peters W, Killick-Kendrick R (eds) The leishmaniasis in biology and medicine, Academic Press, London, p. 848-907, 1987.
4. Carvalho EM, Badaró R, Reed SG, Jones TC, Johnson Jr WD. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. Journal Infection Investigation 76: 2066-2069, 1985.
5. Carvalho EM, Teixeira RS, Johnson Jr WD. Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infection Immunity 33: 498-502, 1981.
6. Chulay JD, Bryceson AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. American Journal of Tropical Medicine and Hygiene 32: 475-9, 1983.
7. Costa CHN, Pereira HF, Araüjo MV. Epidemia de calazar no Estado do Piaui, Brasil. Revista de Saúde Pública 24: 361-372, 1990.
8. Costa CHN, Gomes RBB, Gonçalves MJO, Garcez LM, Ramos PKS, Santos RS, Shaw JJ, David JR, Maguire JH. Competence of human host as reservoir for Leishmania chagasi. Journal of Infectious Disease 182: 997-1000, 2000.
9. Golden MH, Briend A. Treatment of malnutrition in refugee camps. Lancet 342: 360, 1993.
10. Herwaldt BL. Miltefosine - the long-awaited therapy for visceral leishmaniasis? New England Journal of Medicine 341: 1840-1842, 1999.
11. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostan) and review of pertinent clinical studies. American Journal Tropical Medicine and Hygiene 46: 296-306, 1992.
12. Jeronimo SBM, Oliveira RM, Machay S, Costa RM, Sweet J, Nascimento ET, Luz KG, Fernandes MZ, Jernigan J, Pearson RD. An urban outbreak of visceral leishmaniasis in Natal, Brazil. Transaction Royal Society Tropical Medicine Hygiene 88: 386-388, 1994.
13. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fisher C, Voss A, Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. New England Journal of Medicine 341: 1795-1800, 1999.
14. Lachaud L, Dereure J, Chabbert E, Reynes J, Mauboussin JM, Oziol E, Dedet JP, Bastien P. Optimized PCR using patient blood samples for diagnosis and follow-up of visceral leishmaniasis, with special reference to AIDS patients. Journal Clinical Microbiology 38: 236-40, 2000.
15. Liarte DB, Mendonça IL, Luz FCO, Abreu EAS, Mello GWS, Farias TJC, Ferreira AFB, Millington MA, Costa CHN. QBC® for the diagnosis of human and canine American visceral leishmaniasis: preliminary data. Revista da Sociedade Brasileira de Medicina Tropical 34: 577-581, 2001.
16. Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 340: 1256-1257, 1992.
17. Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment in Indian kala-azar. Lancet 344: 1599-1600, 1994.
18. Nyakundi PM, Wasunna KMA, Rashid JR, Gachini GS, Mbugua J, Kirigi G. Muttunga J. Is one year follow-up justified in kala-azar post-treatment? East African Medical Journal 71: 453-459, 1994.
19. Seaman J, Mercer AJ, Sondorp E. Epidemic visceral leishmaniasis in Southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. American College Physicians 124: 664-672, 1996.
20. Sen Gupta PC. Chemotherapy of leishmanial diseases: a resumé of recent research. Indiana Medicine Gazette 88: 20-35, 1953.
21. Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, Engel J, Murray, HW. Oral treatment of visceral leishmaniasis with miltefosine. Annals of Tropical Medicine and Parasitology 93: 589-597, 1999.
22. Thakur CP, Kumar M, Kumar M, Mishra BN, Pandey AK. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. British Medicine Journal 296: 1557-1561, 1988.
23. Thakur CP, Kumar M, Pandey AK. Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study. American Journal of Tropical Medicine and Hygiene 45: 435-441, 1991.
24. Thakur CP, Sinha GP, Sharma V, Pandey AK, Kumar M, Verma BB. Evaluation of amphotericin B as a first-line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kalaazar. Indiana Journal Medical Research 97: 170-175, 1993.
25. Thakur CP, Sinha GP, Sharma V, Pandey AK, Sinha PK, Barat D. Efficacy of amphotericin B in multi-drug resistant kala-azar in children in first decade of life. Indian Journal of Pediatrics 60: 29-36, 1993.
26. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Transaction Royal Society Tropical Medicine Hygiene 93: 319-323, 1999.
27. World Health Organization Experts Committee. Control of the leishmaniasis. Technical Report Series 793, World Health Organization, Geneva, Switzerland, 1990.